Nicoya is a Canadian life sciences tools company specializing in innovative biosensor technology for the academic, biotechnology and pharmaceutical sectors.
Nicoya isdeveloping sensor products that will change the world of biotechnology, life sciences, and healthcare.
Nicoya was founded in 2012 by Ryan Denomme, alongside with Shawn Fitzpatrick. The company is headquartered in Kitchener, Ontario, Canada.
Nicoya's label-free biosensor platform, Alto, integrates surface plasmon resonance (SPR) with digital microfluidics (DMF) to revolutionize the way biologics developers approach biological assays and tackle challenging drug targets.
Nicoya's OpenSPR, is a powerful and affordable instrument for label-free interaction analysis. Nicoya's other product OpenSPR-XT maximize your productivity with fully automated, 24/7 operation of our benchtop SPR.
Nicoya’s solutions are currently being used by over 500 of the world’s leading researchers. The biosensor developer will look to continue expanding in the academic, government, biotechnology, and pharmaceutical sectors.
Nicoya is backed by Whitecap Venture Partners, Agilent Technologies, Export Development Canada, BDC Capital, MaRS IAF, Garage Capital, and others. The company $15.7M in Series A extension on Dec 16, 2021. This brings Nicoya's total funding to $28.2M to date.